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MicroRNAs (miRNAs) are small non-protein-coding RNAs that function as endogenous negative gene regulators. Dysfunctions
of miRNAs are frequently found in malignancies, including lung cancer. In this review, we summarise the current understanding
of miRNAs in lung cancer tumourigenesis, and highlight their potential in overcoming drug resistance, abetting histological
sub-classification techniques, and serving as biomarkers for lung cancer risk stratification and outcome prediction.
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Lung cancer is the leading cause of cancer mortality worldwide, and
80% of lung cancers are non-small cell lung cancers (NSCLCs) (Jemal
et al, 2009). Despite improvements in early diagnosis made possible
by emerging technologies and newly developed chemo/targeted
therapies that improve treatment responses, the overall 5-year
survival for NSCLC patients remains low (15%) and the recurrence
rate is high, even in early-stage groups (Miller, 2005). The poor
prognosis is due to late disease presentation, tumour heterogeneities
within histological subtypes, and our relatively limited under-
standing of tumour biology. Emerging targeted therapies directed
against specific cellular alterations require precise sub-classification
of NSCLCs that is beyond the capabilities of standard histopatho-
logical diagnostic techniques. However, knowledge accumulated
through genomic medicine creates the possibility of unravelling the
remaining mysteries of lung cancer oncogenesis, and opens the door
to molecular classification and risk stratification based on gene
expression profiles and microRNA (miRNA) signatures.
MicroRNAs are small non-coding, endogenous, single-stranded
RNAs that regulate gene expression (Bartel, 2004). Mature miRNAs
and Argonaute (Ago) proteins form the RNA-induced silencing
complex (RISC), which mediates post-transcriptional gene silen-
cing through induction of messenger RNA (mRNA) degradation or
translational inhibition (Liu et al, 2004; Pillai et al, 2004). Target
mRNA specification is determined by sequence complementarity
between the seed sequence of an individual miRNA and the target
mRNAs (Baek et al, 2008; Eulalio et al, 2008; Selbach et al, 2008;
Bartel, 2009). Recent proteomic studies have revealed a broad
spectrum of targets for each individual miRNA (Baek et al, 2008;
Selbach et al, 2008). By regulating gene expression at the post-
transcriptional level, miRNAs profoundly influence a wide variety
of pathways, and their greatest impact is on developmental
and oncogenic pathways (Lee et al, 1993; Wightman et al, 1993;
He et al, 2005, 2007; Johnson et al, 2005; Lu et al, 2005; Calin and
Croce, 2006).
Half of all miRNA genes are found within or near chromosomal
fragile sites, common breakpoints, or minimal regions of loss-of-
heterozygosity or amplification (Calin et al, 2004). Accumulating
evidence shows that miRNAs are grossly dysregulated in human
cancers, including NSCLC, and may serve as oncogenes or tumour
suppressors (Croce, 2009). Recent studies have shown that not only
can miRNAs be used to sub-classify NSCLCs (Bishop et al, 2010) but
specific miRNA profiles may also predict prognosis and disease
recurrence in early-stage NSCLCs (Yanaihara et al,2 0 0 6 ;Y uet al,
2008; Raponi et al, 2009; Seike et al, 2009; Patnaik et al, 2010).
In this review, we briefly describe the biogenesis of miRNAs,
their roles in lung cancer pathogenesis, and their potential use in
NSCLC subgroup classification, risk stratification, and therapy.
The stratification of lung cancer based on miRNA information is
illustrated in Figure 1.
MICRORNA BIOGENESIS
MicroRNA genes are evolutionarily conserved and are located
within the introns or exons of protein-coding genes, as well as in
intergenic areas (Rodriguez et al, 2004). Canonically, miRNA genes
are transcribed by RNA polymerase II or III into kilobase-long
primary miRNA transcripts (pri-miRNAs). Pri-miRNAs are
next cleaved into B70 nucleotide-long precursor miRNAs (pre-
miRNAs) by the nuclear microprocessor complex formed by the
RNase III Drosha and DiGeorge syndrome critical region gene 8
(DGCR8). The average human pre-miRNA contains a 33-base-pair
hairpin stem, a terminal loop, and two single-stranded flanking
regions upstream and downstream of the hairpin. Pre-miRNAs are
next transported by the exportin-5/Ran GTPase complex into the
cytoplasm, where miRNAs undergo maturation (Lee et al, 2003,
2004; Yi et al, 2003; Denli et al, 2004). In the cytoplasm, pre-
miRNAs are cleaved by RNase III Dicer into an B22 nucleotide-
long miRNA duplex and are unwound by helicase. The passenger
strand is degraded, and the selected guide strand together with Ago
protein activates RISC, resulting in mRNA degradation or
translational inhibition, depending on the percentage of sequence
complementarity between the miRNA 50-seed and mRNA 30-UTR
element (Hammond et al, 2000; Diederichs and Haber, 2007).
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introns. These so-called ‘mitrons’ skip the Drosha–DGCR8
processing step and are spliced out of their host genes. These
lariats are debranched, refolded into the stem-loop structure of
typical pre-miRNAs, and then enter the canonical pathway
(Okamura et al, 2007; Ruby et al, 2007).
A recent study by Suzuki et al demonstrated that p53 interacts
with the Drosha microprocessor complex through DEAD-box RNA
helicase p68 (DDX5) and facilitates the processing of pri-miRNAs
into pre-miRNAs. This study describes the p53-mediated post-
transcriptional maturation of miRNAs, linking the core tumour
suppressor p53 to the miRNA biogenesis pathway (Suzuki et al,
2009). These findings may provide an explanation for the
widespread miRNA downregulation observed in human cancers,
in which p53 is often dysfunctional (Lu et al, 2005).
DEFECTS IN THE MIRNA BIOGENESIS PATHWAY
AND LUNG CANCER
Drosha, DGCR8, and Dicer are the three best-established regulators
of miRNA processing. Defects in the miRNA biogenesis machinery
may be closely related to oncogenesis. Deletion of Dicer abrogates
the production of mature miRNAs (Bernstein et al, 2003), and
conditional deletion of Dicer1 enhances lung tumour development in
a K-Ras-induced lung cancer mouse model (Kumar et al, 2007). In
2005, Karube et al (2005) reported that reduced Dicer expression
levels were correlated with poor survival in a cohort of 67 surgically
resected NSCLC patients. This correlation has been confirmed in an
ovarian cancer, three breast cancers, and a lung cancer cohort in
which high Dicer and Drosha mRNA expression is associated with
better overall and disease-free survival (Merritt et al, 2008).
MICRORNAS FUNCTION AS TUMOUR SUPPRESSORS
OR ONCOGENES IN LUNG CANCER
Let-7 miRNAs as tumour suppressors
Let-7 was first identified in Caenorhabditis elegans as a regulator
of the timing of cell fate determination (Reinhart et al, 2000).
In C. elegans with mutant let-7, stem cells fail to exit the cell cycle
and differentiate, but continue to divide, a hallmark of cancer cells
(Reinhart et al, 2000). In humans, the let-7 family is a cluster of
miRNAs whose genes map to different chromosomal regions that
are frequently deleted in lung cancer (Calin et al, 2004). Cell
studies have shown that let-7 miRNA overexpression in the A549
cell line inhibits cell growth and reduces cell-cycle progression
(Johnson et al, 2007). In mouse NSCLC xenograft and orthotopic
models, ectopic let-7g expression reduces tumour burden (Kumar
et al, 2008), and intranasal let-7 administration represses lung
adenocarcinoma (AD) formation (Esquela-Kerscher et al, 2008).
Furthermore, reduced let-7 gene expression in NSCLC patients is
correlated with poor prognosis (Takamizawa et al, 2004; Yanaihara
et al, 2006), and a single nucleotide polymorphism in let-7
complementary site 6 of the K-RAS mRNA 30-UTR is significantly
associated with increased risk for NSCLC among moderate
smokers (Chin et al, 2008). Collectively, these observations suggest
a role for let-7 family miRNAs as tumour suppressors. In addition,
let-7 miRNAs negatively regulate multiple oncogenes, including
the RAS (Johnson et al, 2005), MYC (Kumar et al, 2007), and
HMGA2 (Lee and Dutta, 2007), and cell-cycle progression
regulators, such as CDC25A, CDK6, and cyclin D2 (Johnson et al,
2007). Although a corresponding knockout mouse would be
invaluable for in-depth studies of let-7 tumour suppressor
functions, multiple copies of let-7 in the genome make generating
such a model somewhat problematic (Calin et al, 2004).
ALL MEMBERS OF THE MIR-17-92 CLUSTER AND
MIR-31 ARE ONCOGENES
All members of the miR-17-29 cluster (miR-17, miR-18a, miR-19a,
miR-20a, miR-19b-1, miR-92-1) are oncogenes that reside in
13q31.3 (He et al, 2005). These miRNAs cooperate with c-Myc to
accelerate tumour development and help promote tumour
neovascularisation (O’Donnell et al, 2005; Dews et al, 2006). The
miR-17-92 cluster is overexpressed in small-cell lung cancer
(Hayashita et al, 2005). Ebi et al (2009) have confirmed this
relationship and reported the association of miR-17-92 over-
expression with RB inactivation. Their results suggest that this
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Figure 1 Stratification of lung cancer based on microRNA information. NSCLC, non-small-cell lung cancer.
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miR-31 is another example of an miRNA with oncogenic
properties (termed an oncomir) in lung cancer. As reported by
Liu et al, knockdown of miR-31 represses lung cancer cell clonal
growth and in vivo tumourigenicity. Their data show that miR-31
functions as an oncomir by directly repressing the tumour
suppressors LATS2 and PPP2R2A (Liu et al, 2010). This miR-31/
LATS2/PPP2R2A pathway constitutes a new growth regulator in
lung cancer.
MICRORNAS AND CONVENTIONAL CHEMOTHER-
APY FOR NSCLCS
The selection for chemotherapy-resistant cells is often observed
in platinum-based chemotherapy, currently the main regimen in
NSCLC treatment (Seve and Dumontet, 2005), and is a key cause of
chemotherapeutic failure. A recent in vitro study by Galluzzi et al
(2010) showed that miR-630 inhibits p53-regulated pro-apoptotic
signalling pathways that are specifically induced by cisplatin and
carboplatin. This is one example demonstrating that the role of
miRNAs may involve chemo-sensitivity/-resistance determination
and suggesting the possibility that manipulating miRNAs may be
potentially useful to modulate the cancer chemoresistance.
MIRNAS AND TARGETED THERAPIES
Epidermal growth factor receptor (EGFR) signalling and EGFR
mutations have been a major focus of lung cancer studies conducted
during the past 5 years. Epidermal growth factor receptor is one of
the most common proto-oncogenes in lung cancer. Leucine-to-
arginine substitution at position 858 (L858R) and deletion mutants
in exon 19 constitute 90% of lung cancer-specific EGFR-activating
mutations. These mutations induce lung AD in a mouse model
and confer hypersensitivity to EGFR–tyrosine kinase inhibitors
(EGFR–TKIs) in humans (Rosell et al, 2009).
Several recent studies have uncovered a relationship between the
EGFR signalling pathway and miRNAs. Weiss et al (2008) showed
that miR-128b is a direct regulator of EGFR. miR-128b loss-of-
heterozygosity is frequently found in NSCLC patients and is
positively correlated with clinical response and survival after
gefitinib treatment. In addition, Cho et al (2009) showed that
restoration of the tumour suppressor miR-145 inhibits cancer cell
growth in lung AD patients with EGFR-activating mutations.
Furthermore, miR-7, an miRNA frequently downregulated in lung
cancer, has been shown to suppress EGFR and Raf1 mRNA
expression. It also attenuates the activation of Akt and ERK, two
key players in the EGFR signalling pathway, suggesting that miR-7
negatively regulates the EGFR pathway (Webster et al, 2009).
Finally, miR-21 is upregulated under conditions in which EGFR
signalling is activated, especially in the context of EGFR-activating
mutations, and is suggested to be related to lung carcinogenesis in
never smokers (Seike et al, 2009). Growing evidence from miRNA
studies may help clarify the role of the EGFR network in lung
cancer oncogenesis and provide a clue to solve EGFR—TKI
resistance problems.
The Apo2L/tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a member of the TNF family known to
induce apoptosis in a variety of cancers (Schaefer et al, 2007).
Treatment with TRAIL induces programmed cell death in cancer
cells. However, a significant proportion of cancers are resistant to
TRAIL-induced apoptosis through different mechanisms. Garofalo
et al (2009) showed that miR-221 and miR-222 contribute to lung
cancer resistance to TRAIL therapy by downregulating PTEN and
TIMP3 tumour suppressors. These observations hint at the extent
to which a greater knowledge of miRNAs might bring a deeper
understanding of drug-resistance mechanisms, and suggest a
future role for miRNAs as a solution to the drug resistance
problem.




With the emergence of targeted therapies directed against specific
molecular events or entities, accurate classification of tumours into
AD and squamous cell carcinoma (SCC) becomes a necessity.
However, this can be challenging, especially in cases in which biopsy/
aspirate specimens are small or tumours are poorly differentiated.
miR-205 is reported to be a useful marker for differentiating SCC
from non-SCC NSCLCs, with a sensitivity of 96% and specificity of
90%, even in small biopsies from poorly differentiated tumours
(Lebanony et al, 2009; Bishop et al, 2010). Landi et al (2010) also
reported a five-miRNA signature (miR-25, miR-34c-5p, miR-191, let-
7e, and miR-34a) that accurately differentiated SCC from AD, and the
lower expression level of this signature correlated with poor overall
survival among SCC patients. This is a further step beyond the
traditional protein markers used in immunohistochemical diagnosis
of equivocal cases. It is anticipated that miRNA markers will
ultimately also be found for AD.
Risk stratification and outcome prediction
Risk stratification and prognosis assessment have become a major
concern in the era of personalised medicine. Gene expression
profiling has reached a plateau in this regard (Garber et al, 2001;
Shedden et al, 2008), although recent miRNA studies show great
promise (Yanaihara et al, 2006; Yu et al, 2008; Raponi et al, 2009).
Yanaihara et al (2006) reported that high miR-155 and low miR-
let7a-2 expression correlated with poor overall survival in lung AD
patients. Our group also identified a five-miRNA signature
(miR-137, miR-372, miR-182*, miR-221, and let-7a) that correlated
with disease-free survival in a cohort of 122 NSCLC patients
(Yu et al, 2008). In addition, Raponi et al. reported that miR-146b
is a robust predictor of overall survival in SCC. High miR-146
expression correlated with a poor overall survival in SCC patients
and the same trend was also observed in the expression level of
miR-155 among the same group of patients (Raponi et al, 2009).
The pathway prediction of miR-146b-targeted genes revealed a
significant overlap of biological pathways in their previously
reported 50-gene expression signature (Beer et al, 2002; Raponi
et al, 2009). Patnaik et al (2010) also defined an miRNA signature
that predicted post-operative recurrence of stage I NSCLCs. It is
clearly evident from these studies that, as is the case with gene
expression profiling, miRNA signatures suggested by different
groups are almost non-overlapping. This could be because of the
different experimental platforms used (qRT–PCR versus different
miRNA array systems), batch effects inherent in the microarray
experiment itself, and potential ethnic differences in the study
populations, as observed in the EGFR mutation story. More
detailed studies are needed to clarify these issues. In addition, new
modalities, such as next-generation sequencing, may provide tools
to enhance the prospects of miRNA research.
A recent study by Hu et al (2010) reported a four-miRNA signature
(miR-486, miR-30d, miR-1, and miR-499) that predicted survival of
stage I to IIIa NSCLCs. Unlike all previous studies, their miRNAs were
identified in serum using a Solexa platform (Nanjing Medical
University, Nanjing University and Jiangsu Cancer Hospital, Nanjing,
China). Although this represents a relative non-invasive approach,
questions remain as to the representativeness of serum miRNA
profiles in solid cancers, given that this approach fails to identify
miRNAs commonly found in lung cancer tissues.
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Numerous miRNAs are dysregulated in cancers, and a single
miRNA can have multiple targets involved in different oncogenic
pathways. Accumulating evidence also suggests a role for miRNAs
in fighting drug resistance. These properties make miRNAs
attractive targets in cancer therapy. However, the fact that one
miRNA may target hundreds of mRNAs deserves special
consideration, insofar as it implies the possibility of unpredictable
side effects, even if a specific miRNA is effectively targeted. A
greater understanding of miRNA biology and the development of
suitable delivery systems are required to translate these basic
research results into clinical practice. In addition, miRNAs may
abet the histological characterisation of NSCLC differentiation,
especially in cases in which biopsy/aspiration specimens are
inadequate or tumours are poorly differentiated. This is especially
important when targeted therapy is the treatment of choice. Risk
stratification and drug-response prediction are the central
elements of personalised medicine. During recent years, research
has focused mainly on gene expression profiling and a number of
important studies have been published. As gene expression
profiling reaches a plateau and begins to face limitations, miRNA
signature is a rising star that may provide new resolutions to
old problems. It is difficult to say whether miRNA signature
is superior or inferior to gene expression profiling, with respect to
risk stratification and outcome prediction. What is clear, however,
is that the more we understand cancer biology, the more likely
we are to translate these laboratory-oriented studies into
clinical practice. Finally, miRNAs are much more stable in serum
and plasma than in mRNAs, raising the exciting prospect that
miRNAs might be used as non-invasive biomarkers for disease
monitoring and histological classification under specific circum-
stances. Going forward, insights gained from miRNA studies may
open a new era in lung cancer treatments, providing improved
patient selection for targeted agents, and forming the basis for
the development of novel therapeutics and/or early disease
biomarkers.
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